title: Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.
abstract: T cell-mediated immune responses play an important role in the containment of HIV-1 replication. Therefore, an effective vaccine against HIV-1 should be able to elicit high frequencies of virus-specific CD8(+) and CD4(+) T cells. The highly attenuated poxvirus-based vaccine candidate, NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), has been shown to induce and/or expand SIV-specific CD4(+) and CD8(+) T cell responses in both naive and infected macaques. In this study, the immunogenicity of NYVAC-SIV-gpe alone was compared with a combination regimen where priming with an optimized DNA-SIV-gag-env vaccine candidate was followed by a NYVAC-SIV-gpe boost. In macaques immunized with the prime-boost regimen, the extent and durability of CD8(+) T cell response to an immunodominant SIV gag epitope was increased and these animals recognized a broader array of subdominant SIV epitopes in the cytolytic assay. In addition, the prime-boost regimen significantly enhanced the proliferative responses to both SIV gag and env proteins. Thus, the combination of these vaccine modalities may represent a valuable strategy in the development of a vaccine for HIV.
authors.affiliation: Basic Research Laboratory and Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD 20892, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Hel
authors.forename: W P
authors.initials: WP
authors.lastname: Tsai
authors.forename: A
authors.initials: A
authors.lastname: Thornton
authors.forename: J
authors.initials: J
authors.lastname: Nacsa
authors.forename: L
authors.initials: L
authors.lastname: Giuliani
authors.forename: E
authors.initials: E
authors.lastname: Tryniszewska
authors.forename: M
authors.initials: M
authors.lastname: Poudyal
authors.forename: D
authors.initials: D
authors.lastname: Venzon
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: J
authors.initials: J
authors.lastname: Altman
authors.forename: D I
authors.initials: DI
authors.lastname: Watkins
authors.forename: W
authors.initials: W
authors.lastname: Lu
authors.forename: A
authors.initials: A
authors.lastname: von Gegerfelt
authors.forename: B K
authors.initials: BK
authors.lastname: Felber
authors.forename: J
authors.initials: J
authors.lastname: Tartaglia
authors.forename: G N
authors.initials: GN
authors.lastname: Pavlakis
authors.forename: G
authors.initials: G
authors.lastname: Franchini
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002478:Cells, Cultured; D003601:Cytotoxicity Tests, Immunologic; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007371:Interferon-gamma / Q000096:biosynthesis; D007700:Kinetics; D008213:Lymphocyte Activation; D008253:Macaca mulatta; D018449:SAIDS Vaccines / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; C078787:NYVAC vaccine; D018449:SAIDS Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014765:Viral Vaccines; D007371:Interferon-gamma